AI predicts targeted therapy success for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial uses artificial intelligence (AI) to analyze your medical images, genetic tests, and pathology reports to see how well targeted therapy (EGFR-TKI) works after lung cancer surgery. It may help doctors better predict treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had surgery to completely remove lung cancer (called R0 resection).
- Your cancer stage after surgery is IB, IIA, IIB, or IIIA, and it is a type called adenocarcinoma.
- Your tumor has a specific EGFR gene mutation (19 deletion or L858R).
- You are taking or will take an EGFR-TKI targeted therapy pill after surgery.
- Your doctors have clear images, genetic test results, and pathology reports from before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether changes in tiny particles in your blood (called exosomes) can show how well targeted therapy is working for lung cancer with an EGFR mutation. You may be eligible if you have this type of lung cancer and are starting your first treatment with a targeted drug.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial looks at how well a targeted therapy works before surgery for people with EGFR-mutated non-small cell lung cancer. It aims to understand the link between a heart rhythm measure (RVT) and patient outcomes.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.